TerminatedNCT01712646
Daily Intranasal Oxytocin for Childhood-Onset Schizophrenia
Medication studyAges 10–99United States
Understand this study
Who could participate?
Listed age limits: 10 years to 99 years.
- Listed locations
- BethesdaSee all locations and recruitment
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateOctober 5, 2012
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 18
- Sponsor
- National Institute of Mental Health (NIMH)
- Sponsor type
- Government agency
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- United States
- Age range
- From 10 Years to 99 Years
- Official registry ID
- NCT01712646
- Official title
Show the full official title
The Use of Daily, Intranasal Oxytocin for the Treatment of Childhood-Onset Schizophrenia (COS), a Randomized Double-Blind Trial
Recruitment & locations
TerminatedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Bethesda
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is National Institute of Mental Health (NIMH), a government agency.
Does this study involve medication?
Yes. The study involves medication, including Intranasal Oxytocin.
Who can participate?
Listed age limits: 10 years to 99 years.
Is this study still recruiting?
The registry lists this study as terminated.
